Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States

Published:2015-01 Issue:1 Volume:21 Page:46-54
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Delea Thomas E.,Amdahl Jordan,Diaz Jose,Nakhaipour Hamid Reza,Hackshaw Michelle D.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India;JCO Global Oncology;2023-02

2. ÖDEYİCİ KURUM BAKIŞ AÇISIYLA İLERİ EVRE BÖBREK KANSERİNDE KAYNAK KULLANIMI: EĞİTİM VE ARAŞTIRMA HASTANESİ ÖRNEĞİ;Süleyman Demirel Üniversitesi Vizyoner Dergisi;2022-02-15

3. Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan;Journal of Pharmaceutical Health Services Research;2021-11-01

4. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy;Journal of Medical Economics;2020-11-05

5. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.;The Oncologist;2020-09-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP